Cellprothera

🚨 Dernier jour pour tenter d'obtenir un soutien publicitaire d'une valeur de 100 000 euros ! L'un des gains possibles grâce aux Trophées PME RMC* ! 🏆 Les entreprises lauréates de cette 15ème édition bénéficieront, en plus d’une couverture médiatique, d’un soutien publicitaire conséquent sur RMC Info Talk Sport. Inscrivez-vous ici : https://lnkd.in/e-RUqXeh *Concours gratuit et accessible à toutes les TPE/PME Cc Trophées PME RMC, Afnic - Internet Made In France

🗞 HOT OFF THE PRESS: In case you missed it, we are delighted to have launched our long-term study on ProtheraCytes® efficacy and safety! The PERFECT study will monitor patients post-Phase I/IIb success, focusing on cardiac tissue repair and regeneration following severe heart attacks. 👀 To find out more, read the full story via PharmiWeb.com: Life Science News & Resources: https://bit.ly/3WMwfq0 #CardiovascularHealth #CellTherapy #ClinicalTrials #Cardiology #AMI #HeartAttack

Hope everyone had a great week! I wanted to share some of this weeks Life Science Industry Highlights: Apollomics updated their strategic focus and announced key leadership changes, aiming to streamline operations and prioritize their lung cancer trials. Cerus welcomed Dean Gregory Gregory to their Board of Directors, bringing in new expertise to drive forward their mission. Mendel.ai unveiled a groundbreaking neuro-symbolic AI system, outperforming GPT-4 in a new study for automatic cohort retrieval. Semnur Pharmaceuticals, Inc., a subsidiary of Scilex Holding Company, and Denali Capital Acquisition Corp. (Nasdaq: DECA) signed a letter of intent for a proposed business combination. Adicet Bio, Inc Bio received FDA Fast Track Designation for ADI-270 in metastatic/advanced clear cell renal cell carcinoma, accelerating the development of this promising treatment. AusperBio highlighted major advances in the clinical development of AHB-137. Biostar Pharmaceuticals Inc Pharma got FDA clearance for an IND application for a Phase 2 study of Utidelone Injection (UTD1) in HER2- breast cancer brain metastasis. CellProthera SAS and BioCardia, Inc. successfully collaborated on a Phase II trial of ProtheraCytes for treating acute myocardial infarction. #Biotech #Pharma #LifeScience #HealthcareInnovation #AIinHealthcare #ClinicalTrials #FDAApproval #Biopharma #LifeSciences #MedicalResearch #DrugDevelopment #HealthTech #Biotechnology #Pharmaceuticals #BiotechNews #Innovation #Healthcare #MedTech #ResearchAndDevelopment

Today, Cellprothera is delighted ..... 😃 ...to reach the milestone of 3,000 enthusiasts following its development and progress. A special mention to Mrs Delhia GIGAN, who will remain the 3000th in our hearts! Thank you so much for following us in ever greater numbers, and for your interest and kindness. 🙏🏼 #technology #innovation #health #france2030 #creativity Find all our news on linkedin and: https://lnkd.in/eecKXqes

🚨NEWS!   We are thrilled to announce promising Phase II trial results for ProtheraCytes in treating acute myocardial infarction (AMI). The EXCELLENT trial demonstrated that our autologous CD34+ stem cells, delivered via BioCardia, Inc.’s Helix percutaneous catheter system, significantly improve heart function and prevent heart failure progression with no unexpected serious adverse events.   Following this success, we look forward to advancing to Phase III to further enhance cardiovascular health.   👀Read the full story, via Cardiac Interventions Today: https://bit.ly/3zxnQ0y   #CardiovascularHealth #CellTherapy #ClinicalTrials #Cardiology #AMI #HeartAttack

Vous n’êtes pas connectés ??? Rejoignez-nous vite ! #cellprothera #innovation #francebiolead #efs

Magnifique webinaire en cours ! De grand experts de la thérapie cellulaire sont avec nous, c’est un moment unique dont il faut profiter ! #sante #france2030 #innovation #startup #celltherapy

Vous n’êtes pas connectés ??? Rejoignez-nous vite ! #cellprothera #innovation #francebiolead #efs

Soyez nombreux à nous rejoindre pour ce webinaire dans lequel CellProthera sera le cas concret de la production de biomédicaments #regenerationcardiaque #ProtheraCytes

🗓 Ne manquez pas cette opportunité unique de vous immerger dans le monde de la #bioproduction et de rencontrer des experts du domaine. 🔎 Pour en savoir plus et trouver un événement près de chez vous parmi les 29 engagés dans les 11 régions de France, consultez notre carte interactive ! #JNBB2024 #attractivité France BioLead